(Press-News.org) Prostate cancer patients carrying inherited mutations in the BRCA genes respond less well to conventional treatment, including surgery and/or radiotherapy - and they also have a lower survival rate than those who are non-carriers of these genetic mutations. Data from the study, which has been published in the journal European Urology, points to the need for new clinical trials aimed at targeting these mutations in order to tailor treatment for these patients.
The study has been led by David Olmos and Elena Castro at the Spanish National Cancer Research Centre (CNIO) and Rosalind Eeles at the Institute of Cancer Research & Royal Marsden NHS Foundation Trust in the UK.
10-YEAR SURVIVAL REDUCED BY HALF
The findings originate from a 2013 study published by the same group of researchers in which they observed that patients carrying inherited mutations in the BRCA genes suffered from more aggressive tumours and died earlier. "That was when we found the first genetic factor associated with prostate cancer prognosis," explains Castro (for further information: http://www.cnio.es/es/news/docs/david-olmos-journal-clinical-oncology-9abr13-en.pdf)
It was then that the researchers decided to conduct a more in-depth study of patients with inherited BRCA mutations and the treatments applied to them, radiotherapy or surgery. According to the article, the results are unambiguous: regardless of the treatment received, patients with tumours at a localised stage (that is, non-metastatic tumours) do not respond as well to the current treatments as patients not carrying the mutations.
Over 1,300 patients participated in the study, 67 of whom were carriers of BRCA mutations. Patients carrying such mutations who had undergone radiotherapy showed 10-year survival rates of 39%, compared to 80% for non-carriers. Amongst patients who have undergone surgery the difference in 10-year survival rates is less pronounced (91% vs. 67%; see table); the smaller difference in survival rates among carriers and non-carriers who have undergone surgery shows that "these patients may require more long-term monitoring to establish whether or not this difference is significant," argues Castro.
CHANGE OF TREATMENT STRATEGY FOR THESE PATIENTS
Still to this day, the prognostic factors that would help determine a more personalised treatment are unknown. Smaller, less aggressive tumours are surgically removed; larger and/or more aggressive tumours are treated using surgery and radiation therapy. "An important issue is that during consultation we usually cannot predict which patients will evolve less favourably and which will live less time than others," the researcher explains. The team's objective is to identify the subgroup of patients with the least favourable prognosis and the treatments that best match their genetic characteristics.
BRCA genes produce proteins that block tumour development, thereby guaranteeing the stability of the genetic material in cells; when the DNA gets damaged by environmental, hereditary or other factors, BRCA proteins come into play to fix it and therefore guarantee the survival of the cells. Specific mutations in these genes prevent damaged cells from repairing the DNA efficiently and have been associated with various types of cancer, including breast, ovarian and prostate cancer.
PARP inhibitors are used as tools for specifically targeting the destruction of tumour cells with BRCA mutations. These molecules, which are currently in clinical trials for the treatment of prostate cancer, are proving to be very effective in the treatment of breast and ovarian cancer when there are BRCA mutations. Furthermore, "prostate tumours with sporadic mutations [present only in the tumour, not inherited] in BRCA, also respond to these inhibitors, according to recent data presented during the ESMO [European Society for European Oncology] congress in Madrid," states Olmos.
The conclusions of this study underline the importance of launching clinical trials designed to assess new treatment strategies and the therapeutic potential of novel drugs for prostate cancer in these patients, such as PARP inhibitors.
CLOSER MONITORING
This study has focused on prostate cancer patients with hereditary BRCA mutations. "We are investigating whether patients with sporadic mutations in these genes also show more aggressive and metastatic tumours, and whether or not they respond less well to conventional treatments than patients not carrying BRCA mutations."
If this hypothesis is confirmed "there would be a need for closer monitoring of patients with BRCA mutations, regardless of the origin [hereditary or sporadic], in order to improve the clinical course of these patients."
Prostate cancer is the second most common form of cancer affecting men in the world - and the most common in some countries, including Spain, where 25,000 new cases are diagnosed every year. It is believed that 2% of these patients are carriers of hereditary BRCA mutations, while 12% of the patients have sporadic mutations in the same genes.
The relevance of this work and its implications for the improved care of prostate cancer patients were recognised last year at the Genitourinary Cancers Symposium organised by the American Society of Clinical Oncology (ASCO), which awarded the preliminary research work a Merit Award.
INFORMATION:
The study has been financed by the Ronald and Rita McAulay Foundation, the CRIS Foundation for Cancer Research, the Spanish Association against Cancer (AECC), the GAME-ON initiative, and the European Union.
Reference article:
Effect of BRCA mutations on metatastatic relapse and cause-specific survival after radical treatment for localized prostate cancer. Elena Castro, Chee Goh, Daniel Leongamornlert, Ed Saunders, Malgorzata Tymrakiewicz, Tokhir Dadaev, Koveela Govindasami, Michelle Guy, Steve Ellis, Debra Frost, Elizabeth Bancroft, Trevor Cole , Marc Tischkowitz, M. John Kennedy, Jacqueline Eason, Carole Brewer, D. Gareth Evans, Rosemarie Davidson, Diana Eccles, Mary E. Porteous, Fiona Douglas, Julian Adlard, Alan Donaldson, Antonis C. Antoniou, Zsofia Kote-Jarai, Douglas F. Easton, David Olmos, Rosalind Eeles. European Urology (2014). doi: 10.1016/j.eururo.2014.10.022
November 14, 2014 - After the Boston Marathon bombings, more than 100 people were treated for trauma affecting the ears and hearing--with many having persistent or worsening hearing loss or other symptoms, reports a study in the December issue of Otology & Neurotology. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Dr. Aaron Remenschneider and principal investigator Dr. Alicia Quesnel of Massachusetts Eye and Ear Infirmary led a Boston-wide collaboration that reviewed the experience with otologic injuries caused by the 2013 ...
This news release is available in German. For their study, the scientists investigated diseased nerve cells using high precision methods and subsequently simulated their electrical properties on the computer. In their view, medical interventions that preserve the structural integrity of neurons may constitute an innovative strategy for the treatment of neurodegenerative diseases.
Inside the brain, the nerve cells, which are also called "neurons," are woven into a network in which they relay signals to one another. Thus, neurons form intricate projections that enable ...
This interview was conducted in August, released as a Web First, and appears in the November issue of Health Affairs.
Health Affairs has previously published Cheng's interviews with other world health ministers, including Thomas Zeltner of Switzerland (2010) and Chen Zhu of China (2012).
In this interview, Minister Nguyen noted that the Vietnamese parliament has voted to spend about 30 percent of the country's state fund for public health. However, that goal has yet to be reached. She also confirmed that Vietnam's 2008 Law of Health Insurance requires patients use ...
Managing childhood asthma is difficult. Rather than giving daily medications -- even when children feel well -- many parents treat asthma only when symptoms become severe. This practice can lead to missed school days, trips to the ER and hospitalizations.
But a novel program at Washington University School of Medicine in St. Louis suggests that peer trainers who coach parents over the phone on managing their children's asthma can sharply reduce the number of days the kids experience symptoms. The program also dramatically decreased ER visits and hospitalizations among ...
DUBLIN, Ireland, November 14th, 2014 - TB is an infectious disease that kills 1.5 million people each year, and smoking is the biggest driver of the global TB epidemic. Medical scientists at Trinity College Dublin and St James's Hospital in Ireland have unlocked the mechanism underlying the connection between smoking and Tuberculosis (TB). This discovery will considerably strengthen anti-smoking efforts to control TB and uncovers new therapy and vaccine options for TB. Their research has just been published in the top respiratory Journal, the American Journal of Respiratory ...
Philadelphia, PA (November 14, 2014) -- Sleep apnea may accelerate kidney function decline in diabetic patients with kidney disease, according to a study that will be presented at ASN Kidney Week 2014 November 11¬-16 at the Pennsylvania Convention Center in Philadelphia, PA.
Type 2 diabetes often contributes to the development of chronic kidney disease (CKD). Because obstructive sleep apnea is common in patients with type 2 diabetes, investigators wonder whether disordered sleep might play a role in the link between diabetes and kidney dysfunction. To investigate, ...
Philadelphia, PA (November 14, 2014) -- Many young patients with chronic conditions don't take their medications correctly, but 2 new studies point to ways to address such medication non-adherence. The studies will be presented at ASN Kidney Week 2014 November 11¬-16 at the Pennsylvania Convention Center in Philadelphia, PA.
In one study, researchers led by Frederick Kaskel, MD, PhD (Albert Einstein College of Medicine) and Oleh Akchurin, MD (Weill Cornell College of Medicine) looked to see how young patients are using smart phones to help them take their medications. ...
WASHINGTON, Nov. 14, 2014--Quick Response (QR) codes -- the box-shaped symbols that appear on signs, posters, and even business cards -- are a convenient and efficient way of accessing specific web pages with a smartphone or other mobile device. However, new research published today in The Optical Society's (OSA) new high-impact journal Optica, explains how QR codes can do much more.
By adding an array of tiny lenses to an ordinary smartphone, a team of optical engineers from the University of Connecticut has found a way to securely display three-dimensional (3-D) images ...
Researchers at the University of Liverpool have found that screening for Ebola at airports could be an effective method for preventing the spread of the disease into the UK and US, but due to the long incubation period of the virus, screening won't detect all cases.
Published in the Lancet medical journal, the study used a mathematical model to test the probability of infected travellers from West Africa entering the UK and US.
The team, from the University's Institute of Infection and Global Health, examined the current growth rate of the epidemic in West Africa alongside ...
People with bipolar disorder who are being treated with the drug lithium are at risk of acute kidney damage and need careful monitoring, according to new research from the University of East Anglia (UEA) and Norfolk and Suffolk NHS Foundation Trust.
Lithium is a mainstay treatment for bipolar disorder and it is known that the drug can cause a loss of kidney function. The new research establishes the link between short-term exposure to high levels and potential damage to the kidneys.
It is still not known what the impact of more than a single exposure to high levels ...
